Back to results
US 2026/0200890 A1Published application
Adar1 inhibitors and methods of using the same
AssigneesAvammune Therapeutics Inc, Aten Porus Lifesciences Pvt. Ltd.
InventorsAditya KULKARNI, Sandeep GOYAL, Avijit GOSWAMI, Kawaljit SINGH, Princy KHURANA
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds identified as inhibitors of ADAR1 activity, such as compounds having the formula: or a pharmaceutically acceptable salt or tautomer thereof, that are useful in treating cancer and other disorders, include those related to abnormal ADAR1 expression.
Claims56
A compound of Formula (I) having the structure:
- or a pharmaceutically acceptable salt or tautomer thereof,
- wherein:
- L is a linker having structure -A-L1-B—,
- wherein:
- A is, —NRc—, —NRcC(O)—, —C(O)NRc—, —NRcS(O)2—, or —S(O)2NRc—;
- L1 is absent, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- B is a bond, —NRd—, —N(S(O)2-alkyl)-, —NRdC(O)—, —OC(O)—,
- —OC(CF3)—, —O—, —C(O)-alkylene-, —C(O)—, —NRdS(O2)—, —S(O2) NRd—, or heteroaryl;
- Rc and Rd are each independently H, alkyl, cycloalkyl, heterocyclyl, alkylene-aryl, acyl, or sulfonyl,
- with the proviso that -A-L1-B— does not contain an —O—O, —NRc—O, —O—NRd—, —NRc—NRd—, or S—S bond;
- X is C—R1 or N;
- Y is C—R4 or N;
- Z is O, S, N—R5, or N(R5)—CH2—;
- Z3, Z4, Z5, Z6, and Z7 are each independently N or CH, wherein no more than 2 of Z3, Z4, Z5, Z6, and Z7 are N;
- R1 is H, halogen, alkyl, —CN, —C(O)Ra, —C(O)ORa, —C(O)NHRa, —C(O)N(alkyl)(Ra), —C(O)N(Ra)(Ra), —C(O)NRaRa, or —S(O)2Ra, or —S(O)2ORa, or R1 and Rc taken together with the atoms to which they are attached form a heterocyclyl or heteroaryl;
- R2 is H, halogen, alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, or heterocycloalkenyl;
- R3 is each independently halogen, —OH, —CH2OH, alkyl, haloalkyl, alkoxy, haloalkoxy, —S(O)2NHRb, —S(O)2NRbRb, —NHS(O)2Rb, —C(O)Rb, —C(O)ORb, —C(O)NHRb, —C(O)NRbRb, —NHC(O)Rb, —NHC(O)NRbRb, —CN, or —P(O)(ORb)2, or two R3 taken together with the adjacent carbon atoms to which they are attached form an aryl, cycloalkyl, or heterocyclyl;
- R4 is H, halogen, alkyl, —C(O)ORa, —C(O)NHRa, or aryl, or R2 and R4 taken together with the carbon atoms to which they are attached form a cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- R5 is H, alkyl, alkylenecycloalkyl, cycloalkyl, aryl, alkylenearyl, or heteroaryl, or R2 and R5 taken together with the adjacent carbon atoms to which they are attached form an aryl or heteroaryl;
- Ra is each independently H, alkyl, cycloalkyl, alkylene-cycloalkyl, aryl, heteroaryl, alkylene-aryl, or alkylene-heteroaryl, or two Ra groups taken together with the nitrogen atom to which they are attached form a heterocyclyl;
- Rb is H, alkyl, cycloalkyl, alkylene-cycloalkyl, heterocyclyl, or aryl, or two Rb groups taken together with the nitrogen atom to which they are attached form a heterocyclyl;
- and
- m is 0, 1, 2, or 3,
- wherein the compound is not:
21 more elements
Dependencies are inferred from the claim text.